LDS/Medical Tests/Beta-2 Adrenergic Receptor (ADRB2) Gene Variation

Beta-2 Adrenergic Receptor (ADRB2) Gene Variation

Beta-2 Adrenergic Receptor (ADRB2) is one of the 7 transmembrane protein families and is coded by the gene ADRB2 located at 5q32. ADBR2 is a G protein-coupled receptor (GPCR) whose ligands are epinephrine (adrenalin) and norepinephrine (noradrenalin). Epinephrine is a positive agonist and is initiates physiologic responses via ADRB2, which upon epinephrine binding, the receptor activates the underlying G-protein and stimulates adenylate cyclase to produce cyclic-AMP (cAMP). This in turn activates cAMP-dependent protein kinases which causes smooth muscle relaxation, pupillary dilatation and vasodilation. In the gastrointestinal system, it decreases motility and inhibits digestion. In the bronchi, it causes bronchodilation. It is also responsible for increased glucose release from the liver as well as increased glucose uptake by tissues.

More than 80 single nucleotide polymorphisms (SNPs) as well as point mutations (gene variations) have been identified that may downregulate the function of ADRB2 and are associated with susceptibility to develop asthma, type 2 diabetes mellitus and obesity. Further, individuals may also be unresponsive to administration of beta-2 agonists. Since the receptor is the target of clinically important drugs for asthma and cardiovascular conditions including hypertension and congestive heart failure. Genetic variations in the ADRB2 gene have been implicated in clinical efficacy of drugs such as long-acting beta2-agonists. The ADRB2 genetic testing assay identifies mutations that are associated with altered receptor function, which has important implications for an individual’s response to certain asthma medications.

Most common variations in the ADRB2 gene and among these, a non-synonymous SNP (rs1042713, G>A, Arg16Gly) has been well characterized in asthma pharmacogenetics. Individuals with two copies of the G allele are considered to have normal ADRB2 expression and function. Individuals with one copy of the G allele and one copy of the A allele and individuals with two copies of the A allele are considered to have downregulation of beta2-AR expression and uncoupling of the resulting receptor.

  • Aids in screening individuals with a familial history of asthma for therapy selection
  • Useful in investigating the unresponsive treatment from asthma therapy (beta-2 agonists)
Homozygous ADRB2 rs1042713 A/A genotype or the heterozygous ADRB2 rs 1042713 G/A genotype have decreased expression and altered function of beta2-AR leading to increased risk of asthma exacerbation when salmeterol or formoterol is used as corticosteroids. Carriers of the ADRB2 rs1042713 A allele may be switched to different types of therapies such as leukotriene receptor antagonists.

ADRB2 rs1042713 G/G (Normal receptor function)

Real-time Polymerase chain reaction (PCR), southern blotting, next-generation sequencing (NGS), and multiplex ligation-dependent probe amplification (MLPA).

Whole blood, Lavender-top (EDTA) tube, buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days
Fasting glucose, HbA1c, serum cortisol, urinary VMA, renal function tests, lipid profile, and thyroid function tests.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login